Switch to Lawrence Mayer's research page...

2004

1. Abraham SA, McKenzie C, Masin D, Ng R, Harasym TO, Mayer LD, Bally MB. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin Cancer Res 10(2):728-38. (2004).
    [View Abstract - PubMed 14760096]  Request Paper

2. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB. pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60 (2004).
    Request Paper

3. Hu Y, Krishan A, Nie W, Sridhar KS, Mayer LD, Bally M. Synergistic cytotoxicity of pyrazoloacridine with Doxorubicin, Etoposide, and topotecan in drug-resistant tumor cells. Clin Cancer Res 10(3):1160-9. (2004).
    [View Abstract - PubMed 14871996]  Request Paper

4. Waterhouse DN, Dragowska WH, Gelmon KA, Mayer LD, Bally MB. Pharmacodynamic Behavior of Liposomal Antisense Oligonucleotides Targeting Her-2/neu and Vascular Endothelial Growth Factor in an Ascitic MDA435/LCC6 Human Breast Cancer Model. Cancer Biol Ther 3(2):1-8. (2004).
    [View Abstract - PubMed 14726684]  Request Paper

2003

5. Chiu GN, Bally MB, Mayer LD. Targeting of antibody conjugated, phosphatidylserine-containing liposomes to vascular cell adhesion molecule 1 for controlled thrombogenesis. Biochim Biophys Acta 1613(1-2):115-21. (2003).
    [View Abstract - PubMed 12832092]  Request Paper

6. Fung VW, Chiu GN, Mayer LD. Application of purging biotinylated liposomes from plasma to elucidate influx and efflux processes associated with accumulation of liposomes in solid tumors. Biochim Biophys Acta 1611(1-2):63-9. (2003).
    [View Abstract - PubMed 12659946]  Request Paper

7. Hu Y, Bally M, Dragowska WH, Mayer L. Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase enhances chemotherapeutic effects on H460 human non-small cell lung cancer cells through activation of apoptosis. Mol Cancer Ther 2(7):641-9. (2003).
    [View Abstract - PubMed 12883037]  Request Paper

8. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP, Mayer LD, LaCasse EC. Antisense Oligonucleotides Targeting XIAP Induce Apoptosis and Enhance Chemotherapeutic Activity against Human Lung Cancer Cells in Vitro and in Vivo. Clin Cancer Res 9(7):2826-36. (2003).
    [View Abstract - PubMed 12855663]  Request Paper

9. Ickenstein LM, Arfvidsson MC, Needham D, Mayer LD, Edwards K. Disc formation in cholesterol-free liposomes during phase transition. Biochim Biophys Acta 1614(2):135-8. (2003).
    [View Abstract - PubMed 12896806]  Request Paper

10. Lopes de Menezes DE, Hu Y, Mayer LD. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. J Exp Ther Oncol 3(2):72-82. (2003).
     [View Abstract - PubMed 12822513]  Request Paper

11. Shabbits JA, Hu Y, Mayer LD. Tumor chemosensitization strategies based on apoptosis manipulations. Mol Cancer Ther 2(8):805-13. (2003).
     [View Abstract - PubMed 12939471]  Request Paper

12. Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 1612(1):98-106. (2003).
     [View Abstract - PubMed 12729935]  Request Paper

13. Shabbits JA, Mayer LD. High ceramide content liposomes with in vivo antitumor activity. Anticancer Res 23(5A):3663-9. (2003).
     [View Abstract - PubMed 14666662]  Request Paper

2002

14. Abraham S, Edwards K, Karlsson G, MacIntosh S, Mayer L, McKenzie C, Bally M. Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta 1565(1):41. (2002).
     [View Abstract - PubMed 12225851]  Request Paper

15. Allen C, Dos Santos N, Gallagher R, Chiu GNC, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS and Bally MB. Controlling the Physical Behavior and Biological Performance of Liposome Formulations through Use of Surface Grafted Poly(ethylene glycol) BioScience Reports, 22(2):225-250. (2002).
     [View Abstract - PubMed 12428902 ]  Request Paper

16. Chiu GN, Bally MB, Mayer LD. Effects of phosphatidylserine on membrane incorporation and surface protection properties of exchangeable poly(ethylene glycol)-conjugated lipids. Biochim Biophys Acta 1560(1-2):37-50. (2002).
     [View Abstract - PubMed 11958774]  Request Paper

17. Denyssevych T, Lestou VS, Knesevich S, Robichaud M, Salski C, Tan R, Gascoyne RD, Horsman DE, Mayer LD, Denyssevych T, Lestou VS, Knesevich S, Robichaud M, Salski C, Tan R, Gascoyne RD, Horsman DE, Mayer LD. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1. Leukemia 16(2):276-83. (2002).
     [View Abstract - PubMed 11840295]  Request Paper

18. Dos Santos N, Mayer LD, Abraham SA, Gallagher RC, Cox KA, Tardi PG, Bally MB. Improved retention of idarubicin after intravenous injection obtained for cholesterol-free liposomes. Biochim Biophys Acta 1561(2):188-201. (2002).
     [View Abstract - PubMed 11997119]  Request Paper

19. Guns ES, Denyssevych T, Dixon R, Bally MB, Mayer L. Drug interaction studies between paclitaxel (Taxol) and OC144-093--a new modulator of MDR in cancer chemotherapy. Eur J Drug Metab Pharmacokinet 27(2):119-26. (2002).
     [View Abstract - PubMed 12064370]  Request Paper

20. Li WM, Mayer LD, Bally MB. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. J Pharmacol Exp Ther 300(3):976-83. (2002).
     [View Abstract - PubMed 11861806]  Request Paper

21. Lopes de Menezes D, Mayer LD. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts. Cancer Chemother Pharmacol 49(1):57-68. (2002).
     [View Abstract - PubMed 11855753]  Request Paper

22. Mayer LD, Lim KT and Hartley D. Identification of Two Distinct Intracellular Verapamil Pools that Contribute to the Modulation of Multidrug Resistant P388-ADR Cells Expressing P-Glycoprotein J. Exp. Therapeut. Oncol., 2:107-120 (2002).
     [View Abstract - PubMed 12415627]  Request Paper

23. Shabbits JA and Mayer LD. P-Glycoprotein Modulates Ceramide-Mediated Sensitivity of Human Breast Cancer Cells to Tubulin-Binding Anticancer Drugs Molecular Cancer Therapeutics, 1:205-213. (2002).
     [View Abstract - PubMed 12467215]  Request Paper

24. Shabbits JA, Chiu GN, Mayer LD. Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems. J Control Release 84(3):161-70. (2002).
     [View Abstract - PubMed 12468219]  Request Paper

2001

25. Chiu GN, Bally MB, Mayer LD. Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol). Biochim Biophys Acta 1510(1-2):56-69. (2001).
     [View Abstract - PubMed 11342147]  Request Paper

26. Guns ES, Bullock PL, Reimer ML, Dixon R, Bally M, Mayer LD. Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes. Eur J Drug Metab Pharmacokinet 26(4):273-82. (2001).
     [View Abstract - PubMed 11808870]  Request Paper

27. Hu Y, Dragowska WH, Wallis A, Duronio V, Mayer L. Cytotoxicity induced by manipulation of signal transduction pathways is associated with down-regulation of Bcl-2 but not Mcl-1 in MCF-7 human breast cancer. Breast Cancer Res Treat 70(1):11-20. (2001).
     [View Abstract - PubMed 11767000]  Request Paper

28. Johnstone SA, Masin D, Mayer L, Bally MB. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta 1513(1):25-37. (2001).
     [View Abstract - PubMed 11427191]  Request Paper

29. Krishna R, Chiu G, Mayer LD. Visualization of bioavailable liposomal doxorubicin using a non-perturbing confocal imaging technique. Histol Histopathol 16(3):693-9. (2001).
     [View Abstract - PubMed 11510957]  Request Paper

30. Krishna R, Mayer LD. Modulation of P-Glycoprotein (PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent Advances in the Design of Selective MDR Modulators Curr. Med. Chem. - Anti-Cancer Agents, 1:163-174. (2001).
     [View Abstract - PubMed 12678765]  Request Paper

31. Krishna R, Webb MS, St Onge G, Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298(3):1206-12. (2001).
     [View Abstract - PubMed 11504822]  Request Paper

32. Li WM, Xue L, Mayer LD, Bally MB. Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes. Biochim Biophys Acta 1513(2):193-206. (2001).
     [View Abstract - PubMed 11470091]  Request Paper

33. Mayer LD, Shabbits JA. The role for liposomal drug delivery in molecular and pharmacological strategies to overcome multidrug resistance. Cancer Metastasis Rev 20(1-2):87-93. (2001).
     [View Abstract - PubMed 11831652]  Request Paper

34. Shabbits JA, Krishna R and Mayer LD. Molecular and Pharmacological Strategies to Overcome Multidrug Resistance Expert Review of Anticancer Therapy, 1(4):585-94 (2001).
     [View Abstract - PubMed 12113091]  Request Paper

35. Waterhouse D N, Tardi P G, Mayer L D, Bally M B. A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 24(12):903-20. (2001).
     [View Abstract - PubMed 11735647]  Request Paper

36. Waterhouse DN, Dos Santos N, Mayer LD, Bally MB. Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs. Pharm Res 18(9):1331-5. (2001).
     [View Abstract - PubMed 11683249]  Request Paper

37. Waterhouse DN, Tardi PG, Mayer LD and Bally MB. Changing Toxicity Profiles: A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form Drug Safety, 24(12):903-920. (2001).
     [View Abstract - PubMed 11735647 ]  Request Paper

2000

38. Chi KC, Wallis AE, Lee CH, Lopes de Menezes D , Sartor J, Dragowska WH, Mayer LD. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat 63(3):199-212. (2000).
     [View Abstract - PubMed 11110054]  Request Paper

39. Dragowska WH, Lopes de Menezes DE, Sartor J, Mayer LD. Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: correlation with Western blot analysis. Cytometry 40(4):346-52. (2000).
     [View Abstract - PubMed 10918285]  Request Paper

40. Johnstone SA, Gelmon K, Mayer LD, Hancock RE, Bally MB. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Anticancer Drug Des 15(2):151-60. (2000).
     [View Abstract - PubMed 10901303]  Request Paper

41. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11(4):265-83. (2000).
     [View Abstract - PubMed 11033070]  Request Paper

42. Krishna R, St-Louis M, Mayer LD. Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC 833) with sterically stabilized liposomal doxorubicin. Int J Cancer 85(1):131-41. (2000).
     [View Abstract - PubMed 10585596]  Request Paper

43. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res 6(7):2891-902. (2000).
     [View Abstract - PubMed 10914739]  Request Paper

44. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Res 60(11):2964-72. (2000).
     [View Abstract - PubMed 10850444]  Request Paper

45. Zhang L, Scott MG, Yan H, Mayer LD, Hancock RE. Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers. Biochemistry 39(47):14504-14. (2000).
     [View Abstract - PubMed 11087404]  Request Paper

1999

46. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol 17(10):3038-47. (1999).
     [View Abstract - PubMed 10506598]  Request Paper

47. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I study of liposomal vincristine. J Clin Oncol 17(2):697-705. (1999).
     [View Abstract - PubMed 10080616]  Request Paper

48. Krishna R and Mayer LD . In vitro Evaluation of Doxorubicin Cytotoxicity and Cellular Uptake in the Presence and Absence of Multidrug Resistance Modulators Pharm. Pharmacol. Commun. 5: 511-517. (1999).
     Request Paper

49. Krishna R, Mayer LD. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Anticancer Res 19(4B):2885-91. (1999).
     [View Abstract - PubMed 10652569]  Request Paper

50. Krishna R, McIntosh N, Riggs KW, Mayer LD. Doxorubicin encapsulated in sterically stabilized liposomes exhibits renal and biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion. Clin Cancer Res 5(10):2939-47. (1999).
     [View Abstract - PubMed 10537363]  Request Paper

51. Mayer LD, Reamer J, Bally MB. Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation. J Pharm Sci 88(1):96-102. (1999).
     [View Abstract - PubMed 9874708]  Request Paper

52. Saxon DN, Mayer LD and Bally MB . Liposomal Anticancer Drugs as Agents to be Used in Combination with Other Anticancer Agents: Studies on a Liposomal Formulation with Two Encapsulated Drugs J. Liposome Res., 9:507-522. (1999).
     Request Paper

1998

53. Bally MB, Lim H, Cullis PR and Mayer LD . Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations J. Liposome Res. 8(3):299-335. (1998).
     Request Paper

54. Embree L, Gelmon K, Tolcher A, Hudon N, Heggie J, Dedhar C, Logan P, Bally MB, Mayer LD. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41(5):347-52. (1998).
     [View Abstract - PubMed 9523729]  Request Paper

55. Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol 42(6):461-70. (1998).
     [View Abstract - PubMed 9788572]  Request Paper

56. Webb MS, Saxon D, Wong FM, Lim HJ, Wang Z, Bally MB, Choi LS, Cullis PR, Mayer LD. Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372(2):272-82. (1998).
     [View Abstract - PubMed 9675310]  Request Paper

1997

57. Cullis PR, Hope MJ, Bally MB, Madden TD, Mayer LD, Fenske DB. Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles. Biochim Biophys Acta 1331(2):187-211. (1997).
     [View Abstract - PubMed 9325441]  Request Paper

58. Embree L, Gelmon KA, Tolcher AW, Hudon NJ, Heggie JR, Dedhar C, Webb MS, Bally MB, Mayer LD. Validation of a high-performance liquid chromatographic assay method for quantification of total vincristine sulfate in human plasma following administration of vincristine sulfate liposome injection. J Pharm Biomed Anal 16(4):675-87. (1997).
     [View Abstract - PubMed 9502163]  Request Paper

59. Krishna R, Mayer LD. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 57(23):5246-53. (1997).
     [View Abstract - PubMed 9393743]  Request Paper

60. Krishna R, de Jong G, Mayer LD. Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin. Anticancer Res 17(5A):3329-34. (1997).
     [View Abstract - PubMed 9413167]  Request Paper

61. Mayer LD, Dougherty G, Harasym TO, Bally MB. The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. J Pharmacol Exp Ther 280(3):1406-14. (1997).
     [View Abstract - PubMed 9067330]  Request Paper

62. Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, Hunter WL. Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs 8(7):696-701. (1997).
     [View Abstract - PubMed 9311446]  Request Paper

1996

63. Mayer LD . Optimized Activity of Liposomal Vincristine (LIPOVINC) Through Liposome Manipulations J. Liposome Res. 6:203-206. (1996).
     Request Paper

1995

64. Alaoui-Jamali M, Wang T, Chen DZ, Mayer LD and Batist G. Effect of Tumor Grafts on Doxorubicin Host Toxicity Cell. Pharmacology, 2:29-33. (1995).
     Request Paper

65. Boman NL, Bally MB, Cullis PR, Mayer LD and Webb MS . Encapsulation of Vincristine in Liposomes Reduces Its Toxicity and Improves Its Anti-Tumor Efficacy J. Liposomes Res., 5,523-541. (1995).
     Request Paper

66. De Jong G, Gelmon K, Bally M, Goldie J, Mayer L. Modulation of doxorubicin resistance in P388/ADR cells by Ro44-5912, a tiapamil derivative. Anticancer Res 15(3):911-6. (1995).
     [View Abstract - PubMed 7645981]  Request Paper

67. Dos Santos N, Cox KA, McKenzie CA, van Baarda F, Gallagher RC, Karlsson G, Edwards K, Mayer LD, Allen C and Bally MB . pH Gradient Loading of Anthracyclines into Cholesterol-Free Liposomes: Enchancing Drug Loading Rates Through Use of Ethanol Biochim Biophys Acta. 1661:47-60. (1995).
     Request Paper

68. Mayer LD, Masin D, Nayar R, Boman NL, Bally MB. Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumours. Br J Cancer 71(3):482-8. (1995).
     [View Abstract - PubMed 7880728]  Request Paper

69. Mayer LD, St-Onge G. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques. Anal Biochem 232(2):149-57. (1995).
     [View Abstract - PubMed 8747469]  Request Paper

70. Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72(4):896-904. (1995).
     [View Abstract - PubMed 7547237]  Request Paper

71. Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta 1238(2):147-55. (1995).
     [View Abstract - PubMed 7548129]  Request Paper

1994

72. Bally MB, Masin D, Nayar R, Cullis PR, Mayer LD. Transfer of liposomal drug carriers from the blood to the peritoneal cavity of normal and ascitic tumor-bearing mice. Cancer Chemother Pharmacol 34(2):137-46. (1994).
     [View Abstract - PubMed 8194164]  Request Paper

73. Boman NL, Masin D, Mayer LD, Cullis PR, Bally MB. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54(11):2830-3. (1994).
     [View Abstract - PubMed 8187061]  Request Paper

74. Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD. Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs. Anticancer Drugs 5(5):579-90. (1994).
     [View Abstract - PubMed 7858291]  Request Paper

75. Mayer LD, Cullis PR and Bally MB . The Use of Transmembrane pH Gradient-Driven Drug Encapsulation in the Pharmacodynamic Evaluation of Liposomal Doxorubicin J. Liposome Res. 4, 529-553. (1994).
     Request Paper

1993

76. Boman NL, Mayer LD, Cullis PR. Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1152(2):253-8. (1993).
     [View Abstract - PubMed 8218326]  Request Paper

77. Embree L, Gelmon KA, Lohr A, Mayer LD, Coldman AJ, Cullis PR, Palaitis W, Pilkiewicz F, Hudon NJ, Heggie JR, et al.. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients. J Pharm Sci 82(6):627-34. (1993).
     [View Abstract - PubMed 8392545]  Request Paper

78. Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs. In Vivo 7(1):17-26. (1993).
     [View Abstract - PubMed 8504204]  Request Paper

79. Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs. In Vivo 7(1):85-95. (1993).
     [View Abstract - PubMed 8504212]  Request Paper

80. Mayer LD, Nayar R, Thies RL, Boman NL, Cullis PR, Bally MB. Identification of vesicle properties that enhance the antitumour activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother Pharmacol 33(1):17-24. (1993).
     [View Abstract - PubMed 8269584]  Request Paper

81. Mayer LD, Pusey ML, Griep MA and Nelsestuen GL . Association of Blood Coagulation Factors V and X with Phospholipid Monolayers Biochemistry, 22, 6266-6233. (1993).
     Request Paper

1991

82. Cullis PR, Bally MB, Madden TD, Mayer LD, Hope MJ. pH gradients and membrane transport in liposomal systems. Trends Biotechnol 9(8):268-72. (1991).
     [View Abstract - PubMed 1367566]  Request Paper

1990

83. Bally MB, Nayar R, Masin D, Cullis PR, Mayer LD. Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes. Cancer Chemother Pharmacol 27(1):13-9. (1990).
     [View Abstract - PubMed 2245488]  Request Paper

84. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, Mayer LD. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochim Biophys Acta 1023(1):133-9. (1990).
     [View Abstract - PubMed 2317492]  Request Paper

85. Madden TD, Harrigan PR, Tai LC, Bally MB, Mayer LD, Redelmeier TE, Loughrey HC, Tilcock CP, Reinish LW, Cullis PR. The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53(1):37-46. (1990).
     [View Abstract - PubMed 1972352]  Request Paper

86. Mayer LD, Bally MB and Cullis PR . Strategies for Optimizing Liposomal Doxorubicin J. Liposome Res. 4, 463-480. (1990).
     Request Paper

87. Mayer LD, Bally MB, Cullis PR, Wilson SL, Emerman JT. Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett 53(2-3):183-90. (1990).
     [View Abstract - PubMed 2208078]  Request Paper

88. Mayer LD, Bally MB, Loughrey H, Masin D, Cullis PR. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50(3):575-9. (1990).
     [View Abstract - PubMed 2297698]  Request Paper

89. Mayer LD, Tai LC, Bally MB, Mitilenes GN, Ginsberg RS, Cullis PR. Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients. Biochim Biophys Acta 1025(2):143-51. (1990).
     [View Abstract - PubMed 2364073]  Request Paper

90. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Anal Biochem 188(1):65-71. (1990).
     [View Abstract - PubMed 2221370]  Request Paper

1989

91. Balazsovits JA, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin. Cancer Chemother Pharmacol 23(2):81-6. (1989).
     [View Abstract - PubMed 2491964]  Request Paper

92. Cullis PR, Mayer LD, Bally MB, Madden TD and Hope MJ . Generation and Loading of Liposomal Systems for Drug Delivery Applications Advanced Drug Delivery Reviews 3, 267-282. (1989).
     Request Paper

93. Mayer LD, Tai LC, Ko DS, Masin D, Ginsberg RS, Cullis PR, Bally MB. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49(21):5922-30. (1989).
     [View Abstract - PubMed 2790807]  Request Paper

94. Redelmeier TE, Mayer LD, Wong KF, Bally MB, Cullis PR. Proton flux in large unilamellar vesicles in response to membrane potentials and pH gradients. Biophys J 56(2):385-93. (1989).
     [View Abstract - PubMed 2775833]  Request Paper

1988

95. Bally MB, Mayer LD, Loughrey H, Redelmeier T, Madden TD, Wong K, Harrigan PR, Hope MJ, Cullis PR. Dopamine accumulation in large unilamellar vesicle systems induced by transmembrane ion gradients. Chem Phys Lipids 47(2):97-107. (1988).
     [View Abstract - PubMed 2457454]  Request Paper

96. Brenner DE, Arakali AV, Mayer LD, Ginsberg RS and Kanter P. Comparison of Liposomal Doxorubicin and Free Doxorubicin Pharmacokinetics in Rabbit Clin. Pharmacol. Therapeut. 43, 125. (1988).
     Request Paper

97. Janoff AS, Kurtz CL, Jablonski RL, Minchey SR, Boni LT, Gruner SM, Cullis PR, Mayer LD, Hope MJ. Characterization of cholesterol hemisuccinate and alpha-tocopherol hemisuccinate vesicles. Biochim Biophys Acta 941(2):165-75. (1988).
     [View Abstract - PubMed 2838079]  Request Paper

98. Mayer LD, Wong KF, Menon K, Chong C, Harrigan PR, Cullis PR. Influence of ion gradients on the transbilayer distribution of dibucaine in large unilamellar vesicles. Biochemistry 27(6):2053-60. (1988).
     [View Abstract - PubMed 3378044]  Request Paper

1987

99. Wong KF, Parmar YI, Mayer LD, Pritchard PH, Cullis PR. Detection of protein-free lipoprotein analogues with an apolar lipid core by freeze-etch electron microscopy. Biochim Biophys Acta 921(2):411-4. (1987).
     [View Abstract - PubMed 3651497]  Request Paper

1986

100. Mayer LD, Bally MB, Cullis PR. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim Biophys Acta 857(1):123-6. (1986).
      [View Abstract - PubMed 3964703]  Request Paper

101. Mayer LD, Bally MB, Hope MJ, Cullis PR. Techniques for encapsulating bioactive agents into liposomes. Chem Phys Lipids 40(2-4):333-45. (1986).
      [View Abstract - PubMed 3742676]  Request Paper

102. Mayer LD, Hope MJ, Cullis PR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta 858(1):161-8. (1986).
      [View Abstract - PubMed 3707960]  Request Paper

103. Richards RL, Habbersett RC, Scher I, Janoff AS, Schieren HP, Mayer LD, Cullis PR, Alving CR. Influence of vesicle size on complement-dependent immune damage to liposomes. Biochim Biophys Acta 855(2):223-30. (1986).
      [View Abstract - PubMed 3753881]  Request Paper

1985

104. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta 816(2):294-302. (1985).
      [View Abstract - PubMed 3839135]  Request Paper

105. Mayer LD, Bally MB, Hope MJ, Cullis PR. Uptake of dibucaine into large unilamellar vesicles in response to a membrane potential. J Biol Chem 260(2):802-8. (1985).
      [View Abstract - PubMed 3968068]  Request Paper

106. Mayer LD, Hope MJ, Cullis PR, Janoff AS. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. Biochim Biophys Acta 817(1):193-6. (1985).
      [View Abstract - PubMed 4005257]  Request Paper

1984

107. Nayar R, Mayer LD, Hope MJ, Cullis PR. Phosphatidic acid as a calcium ionophore in large unilamellar vesicle systems. Biochim Biophys Acta 777(2):343-6. (1984).
      [View Abstract - PubMed 6435674]  Request Paper

1983

108. Mayer LD and Nelsestuen GL . Membrane Lateral Phase Separation Induced by Proteins of the Prothrombinase Complex Biochim. Biophys. Acta 734, 48-53. (1983).
      Request Paper

109. Mayer LD, Nelsestuen GL, Brockman HL. Prothrombin association with phospholipid monolayers. Biochemistry 22(2):316-21. (1983).
      [View Abstract - PubMed 6687431]  Request Paper

1982

110. Pusey ML, Mayer LD, Wei GJ, Bloomfield VA, Nelsestuen GL. Kinetic and hydrodynamic analysis of blood clotting factor V-membrane binding. Biochemistry 21(21):5262-9. (1982).
      [View Abstract - PubMed 7171555]  Request Paper

1981

111. Mayer LD, Nelsestuen GL. Calcium and prothrombin-induced lateral phase separation in membranes. Biochemistry 20(9):2457-63. (1981).
      [View Abstract - PubMed 6786334]  Request Paper

2000

1. Mayer LD . Pharmaceutical Drug Delivery Systems; Medicine's Trojan Horse Helix, 9:48-55. (2000).
    Request Paper

2. Mayer LD, Krishna R, Webb M and Bally MB . Designing Liposomal Anticancer Drug Formulations for Specific Therapeutic Applications J. Liposome Res., 10(2-3):99-115. (2000).
    Request Paper

1998

3. Mayer LD. Future developments in the selectivity of anticancer agents: drug delivery and molecular target strategies. Cancer Metastasis Rev 17(2):211-8. (1998).
    [View Abstract - PubMed 9770118]  Request Paper

In Press

1. Shabbits JA, Hu Y and Mayer LD. Tumor Chemosensitization Strategies Based on Apoptosis Manipulations Molecular Cancer Therapeutics (invited review) (In Press).
    Request Paper

1. Abraham SA, Waterhouse DN, Mayer L, Cullis P, Madden T and Bally MB . Liposomal Formulations of Doxorubicin In: Methods in Enzymology, In Press. (In Press).
    Request Paper

2. Krishna R and Mayer LD . Modulation of p-glycoprotein (PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent Advances in the Design of Selective MDR Modulators In: Current Trends in Medicinal Chemistry - Anticancer Drugs, in press. (In Press).
    Request Paper

3. Waterhouse DN, Bally MB, Mayer LD, Madden TD, Cullis PR and Webb MS. Preparation, Characterization and Biological Analysis of Liposomal Formulations of Vincristine In: Methods in Enzymology, In Press. (In Press).
    Request Paper

2001

4. Mayer LD, Krishna R and Bally, MB . Liposomes for Cancer Therapy Applications In: Polymeric Biomaterials, 2nd Edition (S. Dumitriu, ed.) Marcel Dekker (New York, NY), 823-841. (2001).
    Request Paper

5. Tardi P, Ickenstein L, Bally M and Mayer LD . The Development of Liposomes for Enhanced Delivery of Chemotherpeutics to Tumors In: Cancer Drug Discovery and Development: Tumor Targeting in Cancer Therapy, pp. 119-135 (M. Page, Ed), Humana Press Inc., Totowa, NJ. (2001).
    Request Paper

1998

6. Krishna R and Mayer LD . Applications of Liposome Technology to Overcome Multidrug Resistance in Solid Tumors In: Targeting of Drugs 6: Strategies for Stealth Therapeutic Systems (Ed. G. Gregoriadis), Plenum Press, NY, pp. 95-107. (1998).
    Request Paper

7. Mayer LD, Cullis PR and Bally MB . Designing Therapeutically Optimized Liposomal Anticancer Delivery Systems: Lessons from Conventional Liposomes In: Medical Applications of Liposomes, D.D. Lasic and D Papahadjopoulos, eds., Elsevier, N.Y, pp. 231-257. (1998).
    Request Paper

1997

8. Boman NL, Cullis PR, Mayer LD, Bally MB and Webb MS . Liposomal Vincristine: The Central Role of Drug Retention in Defining Therapeutically Optimized Anticancer Formulations In: Long Circulating Liposomes: Old Drugs, New Therapeutics, G. Storm and M. Woodle, Eds., Lands Bioscience, N.Y., pp 29-49. (1997).
    Request Paper

1996

9. Boman NL, Cullis PR, Bally MB and Mayer LD . Preclinical and Clinical Activity of Liposomal Doxorubicin In: Liposomes in Biomedical Applications (P.N. Shek, ed.) Academic Publishers, Australia, pp.85-103. (1996).
    Request Paper

1995

10. Mayer LD, Gelmon K, Cullis PR, Boman NL, Webb MS, Embree L., Tolcher T and Bally MB . Preclinical and Clinical Studies With Liposomal Vincristine In: Progress in Drug Delivery Systems, Vol. IV, (S. Hirota, ed.) pp. 151-161, Biomedical Research Foundation, Tokyo, Japan. (1995).
     Request Paper

1992

11. Bally MB, Mayer LD, Hope MJ and Nayar R . Pharmacodynamics of Liposomal Drug Carriers: Methodological Considerations In: Liposome Technology, Vol. III. (G Gregoriadis, ed.) pp. 27-42, CRC Press, Inc., Boca Raton, FL. (1992).
     Request Paper

12. Hope MJ, Nayar R, Mayer LD and Cullis PR . Reduction of Liposome Size and Preparation of Unilamellar Vesicle by Extrusion Techniques In: Liposome Technology, Vol. I. (G Gregoriadis, ed.) pp. 123-140, CRC Press, Inc., Boca Raton, FL. (1992).
     Request Paper

13. Mayer LD, Bally MB, Madden TD and Cullis PR . pH Gradient Mediated Drug Entrapment in Liposomes In: Liposome Technology, Vol. II. (G Gregoriadis, ed.) pp. 27-44, CRC Press, Inc., Boca Raton, FL. (1992).
     Request Paper

1988

14. Bally MB, Hope MJ, Mayer LD, Madden TD and Cullis PR . Novel Procedures for Generating and Loading Liposomal Systems In: Liposomes as Drug Carriers. (G Gregoriadis, ed.) pp. 841-853, John Wiley and Sons Ltd., NY. (1988).
     Request Paper

1987

15. Cullis PR, Hope MJ, Bally MB, Madden TD and Mayer LD . Liposomes as Pharmaceuticals In: Liposomes, from Biophysics to Therapeutics. (M Ostro, ed.) pp. 39-72, Marcel Dekker Inc., NY. (1987).
     Request Paper